Alaunos Therapeutics, Inc.
TCRT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TCRT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TCRT
Alaunos Therapeutics, Inc. is a preclinical-stage biotechnology company that has pivoted from oncology cell therapy to developing an oral small-molecule program for obesity and metabolic disorders, currently operating with minimal cash and no approved products.
Key risk: Liquidity and capital risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 11 clinical trials for Alaunos Therapeutics, Inc..
Alaunos Therapeutics, Inc. is a preclinical-stage biotechnology company that has pivoted from oncology cell therapy to developing an oral small-molecule program for obesity and metabolic disorders, currently operating with minimal cash and no approved products.
- Alaunos Therapeutics shifted its strategic focus in August 2023, winding down its TCR-T cell therapy Phase 1/2 trial and reducing its workforce to pursue a preclinical oral small-molecule obesity program [sec_mda · as of 2026-08-14].
- The company's primary asset is a preclinical small-molecule program for obesity and related metabolic disorders, aiming for a differentiated, non-hormonal profile compared to GLP-1-based and other hormonal treatments [sec_mda · as of 2026-03-31].
- As of June 30, 2026, Alaunos had cash and cash equivalents of $0.1M, a net loss of $1.0M for the quarter, and an accumulated deficit of approximately $926.6M since inception [sec_mda · as of 2026-08-14].
- The company's cash burn rate is approximately $0.21 million per month, and existing resources are expected to fund operations only into the third quarter of 2026, with no committed sources of additional capital [sec_mda · as of 2026-08-14].
- Alaunos continues to explore strategic alternatives, including acquisition, merger, reverse merger, sale of assets, or other transactions, to maximize stockholder value [sec · filed 2026-01-08].
What works
- The obesity program targets a large and growing market with a differentiated, non-hormonal oral small-molecule approach, potentially offering a complementary profile to existing GLP-1-based therapies [sec_mda · as of 2026-03-31].
- Management is actively evaluating strategic opportunities and has a committee committed to maximizing stockholder value, indicating a proactive approach to corporate development [sec · filed 2026-01-08].
What to weigh
- Alaunos has no approved products or revenue, and its only pipeline program is at the preclinical stage, with no guarantee of successful clinical translation or regulatory approval [sec_mda · as of 2026-08-14].
- The company faces a severe liquidity crisis: as of June 30, 2026, cash was only $0.1M, with a monthly burn of $0.21M, providing runway only into Q3 2026 and no committed financing sources [sec_mda · as of 2026-08-14].
- The accumulated deficit of $926.6M reflects a history of significant losses, and the company expects to continue incurring net losses for the foreseeable future [sec_mda · as of 2026-08-14].
- Preclinical results are preliminary and may not be predictive of human outcomes; the program is subject to numerous risks and uncertainties inherent in early-stage drug development [sec · filed 2026-01-08].
From the filings
Quoted directly from source documents.
Cash position as of June 30, 2026
“As of June 30, 2026, we had approximately $0.12 million of cash and cash equivalents.”
SEC MD&A · August 14, 2026
Accumulated deficit
“as of June 30, 2026, we have incurred approximately $926.6 million of accumulated deficit since our inception in 2003.”
SEC MD&A · August 14, 2026
Cash burn rate and runway
“Our current monthly cash burn rate is approximately $0.21 million. At this rate we anticipate that our existing cash resources will be sufficient to fund operations into the third quarter of 2026.”
SEC MD&A · August 14, 2026
Strategic pivot from oncology to obesity
“On August 14, 2023, we announced a strategic reprioritization of our business and wind down of our TCR-T Library Phase 1/2 Trial.”
SEC MD&A · August 14, 2026
Risks & what to watch (4)›
Key risks
- Liquidity and capital risk — Cash of $0.1M as of June 30, 2026, provides runway only into Q3 2026; no committed financing sources exist [sec_mda · as of 2026-08-14].
- Preclinical stage uncertainty — The obesity program is preclinical; results are preliminary and may not predict human outcomes, with no IND filed [sec · filed 2026-01-08].
- History of losses — Accumulated deficit of $926.6M and ongoing net losses; no revenue or approved products [sec_mda · as of 2026-08-14].
- Dependence on strategic alternatives — Company is exploring M&A or other transactions, but no guarantee of success or value realization [sec · filed 2026-01-08].
What to watch
- Preclinical data updates for the obesity program, which could determine whether the company advances to IND-enabling studies [sec · filed 2026-01-08].
- Cash runway status: with only Q3 2026 coverage, any delay in financing or strategic deal could force operational cessation [sec_mda · as of 2026-08-14].
- Announcement of a strategic transaction (e.g., merger, reverse merger, asset sale) as the company actively explores alternatives [sec · filed 2026-01-08].
- Potential appointment of new board members, as the company has a committee evaluating opportunities to maximize stockholder value [sec · filed 2026-01-08].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Alaunos Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Alaunos Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
2.9 months
D/E 1.33 · 0% dilution
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Short Interest
as of Apr 21, 2026- % of float
- 0.6%
- Days to cover
- 0.8
- Shares short
- 14,162
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TCRT short interestGovernance
Frequently asked questions
What is the AI investment thesis for Alaunos Therapeutics, Inc.?
Alaunos Therapeutics, Inc. is a preclinical-stage biotechnology company that has pivoted from oncology cell therapy to developing an oral small-molecule program for obesity and metabolic disorders, currently operating with minimal cash and no approved products.
What is Alaunos Therapeutics, Inc.'s lead drug candidate?
Alaunos Therapeutics, Inc.'s most advanced tracked candidate is aln1003 (Preclinical) for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD).
Who is the CEO of Alaunos Therapeutics, Inc.?
Mr. Holger Weis CPA is the chief executive officer of Alaunos Therapeutics, Inc. (TCRT).
Where is Alaunos Therapeutics, Inc. headquartered?
Alaunos Therapeutics, Inc. (TCRT) is headquartered in Fort Lauderdale, FL, United States.
What therapeutic areas does Alaunos Therapeutics, Inc. focus on?
Alaunos Therapeutics, Inc. develops therapies across Oncology, Metabolic, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.